000 05567cam a2200469Ii 4500
001 96276
003 ES-MaUEC
005 20230102112747.0
006 m o d
007 cr cnu|||unuuu
008 170630t20172017sz ob 000 0 eng d
020 _a3319579428
020 _a3319579436
_q(electronic bk.)
020 _a9783319579429
020 _a9783319579436
_q(electronic bk.)
020 _z9783319579429
040 _aN$T
_cN$T
_dEBLCP
_dN$T
_dGW5XE
_dUAB
_dYDX
_dAZU
_dUPM
_dOCLCF
_dMERER
_dESU
_dOCLCQ
_dCOO
_dOCLCQ
_dVT2
_dIOG
_dJG0
_dOCLCO
_dOCLCA
_dES-MaUEC
_bspa
066 _c(S
050 4 _aRC280.B8
_b2017 EB
245 0 0 _aPerioperative inflammation as triggering oigin of metastasis development
_cMichael W. Retsky, Romano Demicheli, editors.
264 1 _aCham, Switzerland
_bSpringer
_c[2017]
264 4 _c2017
300 _a1 recurso en línea
336 _aTexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
347 _atext file
_bPDF
500 _aSpringerLink
_bSpringer Biomedical and Life Sciences eBooks 2017 English+International
504 _aIncluye referencias bibliográficas
505 0 _6880-01
_aForeword; Preface; Contents; Contributors; Introduction; Chapter 1: The Natural History of Breast Cancer; 1.1 Introduction; 1.2 The Nature of Models and Models of Nature; 1.2.1 The Natural History of a Rose; 1.2.2 Breast Cancer; 1.2.3 Breast Cancer in the Nineteenth Century and Early Twentieth Century; 1.2.4 The Influence of Surgery on the Natural History of Breast Cancer; 1.2.5 The Biological Revolution of the Late Twentieth Century; 1.2.6 Phenomena that Challenge the Existing Models; 1.2.6.1 Local Treatment; 1.2.7 Adjuvant Systemic Therapy Has Only a Modest Effect on Survival.
505 8 _a1.2.8 When Does a Primary Tumour Seed Its Secondaries?1.2.9 A new Model to Explain the Natural History of Breast Cancer; 1.2.10 The Nature of Beauty and the Beauty of Nature; References; Chapter 2: Perioperative Inflammation as Triggering Origin of Metastasis Development; 2.1 Introduction; 2.2 Milan Data Showing Early Bimodal Relapse Pattern That Started This Investigation; 2.3 Multipeak Relapse Data Suggest Continuous Growth Is Not a Correct Description of Spontaneous Cancers; 2.4 Library Research at University of Texas-San Antonio; 2.5 Ingleby and Moore Data.
505 8 _a2.6 It Seems We Have Rediscovered a Problem That Was Known to Surgeons 2000 Years Ago2.7 Clinical Correlations to Suggested Surgery Induced Metastatic Activity; 2.8 Surprising Development from a Belgian Anesthesiology Group; 2.9 Our Attention Is Drawn to Inflammation; 2.10 Possible Mechanisms for a Post-surgical Systemic Inflammatory Reaction to Drive Tumor Growth; 2.11 TNBC and Early Relapses: Possibly an Ideal Group for Testing Perioperative Ketorolac; 2.12 Current Activities; 2.12.1 Focus on India and Nigeria; 2.13 Analysis of Data from Norway on Relapse Hazard After Delayed Reconstruction.
505 8 _a3.4 Comparative Analysis of Angiogenesis-Related Genes in Patients with Breast Cancer (Study Group) Before Surgery (PRO) and on Post-operative Day 3 (D3)3.5 Comparative Analysis of Angiogenesis-Related Genes in Patients with Breast Cancer (Study Group) Between Post-operative Day 3 (D3) and Post-operative Day 7 (D7); 3.6 Conclusions; References; Chapter 4: Perioperative Biologic Perturbation and Cancer Surgery: Targeting the Adrenergic-Inflammatory Response and Microcirculatory Dysregulation; 4.1 Introduction; 4.2 Importance of the Perioperative Period to Cancer Outcomes.
520 3 _aThe book will explain previously unconnected clinical data such as why mammography works better for women age 50-59 than it does for women age 40-49, why adjuvant chemotherapy works best for premenopausal patients with positive lymph nodes, and it may also explain the racial disparity in outcome. In particular, it points to the perioperative period when systemic inflammation persists for a week or so. This can lead to a variety of mechanisms whereby single cancer cells (perhaps from the marrow) begin division and angiogenesis of dormant avascular micrometastases occurs leading to early relapses. With chapters presented from distinguished scientists and physicians in a variety of specialties that relate to and border the effects we present, this volume can be used as a reference for practicing physicians and as a jumping-off point for researchers to explore new therapeutic opportunities.
650 7 _aMamas
_xCáncer
_2embne
_0(OCoLC)fst00838260
_0
_9182522
700 1 _aDemicheli, Romano,
_eeditor literario
700 1 _aRetsky, Michael W.,
_eeditor literario
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-57943-6
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
880 8 _6505-01/(S
_a2.14 Concerns About Bleeding Complications2.15 Summary; 2.16 Conclusions; References; Chapter 3: Peri-operative Shift in Angiogenesis-Related Factors in Breast Cancer Patients; 3.1 Study Outline; 3.2 Special Considerations Regarding Study Design; 3.2.1 VEGF (Vascular Endothelial Growth Factor); 3.2.2 IL-8 (Ιnterleukin-8); 3.2.3 bFGF (Basic Fibroblast Growth Factor); 3.3 Comparative Analysis of Angiogenesis-Related Genes Between Patients with Breast Cancer and Fibroadenoma Using Quantitative Real Time PCR; 3.3.1 Study Group vs Control Group Before Surgery (PRO).
988 _aEBOOK, asignarmaterias, EBSPRINGER_2017D
998 _b02/2018
_dz
_e-
_zSI
999 _c96276
_d96276
_x1